89bio qtrly loss per share $2.58

89bio reports fourth quarter and full year 2019 financial results and provides corporate update.89bio inc - qtrly loss per share $2.58.89bio - topline data from phase 1b/2a nonalcoholic steatohepatitis (nash) study expected in h2 2020.
ETNB Ratings Summary
ETNB Quant Ranking